吡柔比星联合化疗方案治疗急性髓细胞性白血病的疗效观察

CURATIVE EFFECT OF TA REGIMEN ON ACUTE MYELOGENOUS LEUKEMIA

目的 观察吡柔比星联合化疗方案对急性髓细胞性白血病的疗效。方法 设治疗组 (吡柔比星联合阿糖胞苷 ,TA组 )和对照组 (柔红霉素联合阿糖胞苷 ,DA组 ) ,治疗组 32例 ,对照组 2 9例。结果 TA组有效率 87 50 % ,DA组有效率 82 76 % (P >0 .0 5) ,TA方案的心脏副作用小于DA方案 (P <0 .0 5)。

Objective\ To observe the curative effect to acute myelogenous leukemia (AML) of the pirarubicin united Ara-C (TA) regimen.Methods\ 32 AML patients received TA and the other 29 patients received daunorubicin united Ara-C(DA) regimen.Results\ The effective rate were 87.50% in patients received TA,and 82.76% in patients received DA respectively(P>0.05).The side effects to the heart of TA regimen were fewer than the DA regimen.Conclusion\ TA is an available regiment to cure the AML.